You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
魯抗醫藥(600789.SH):持有生物技術開發公司的股權比例降至35% 不再納入合併報表範圍
格隆匯 03-12 19:27

格隆匯 3 月 12日丨魯抗醫藥(600789.SH)公佈,之前公吿披露,公司20201030日召開第九屆董事會第十九次(臨時)會議,審議通過了《關於山東魯抗生物技術開發有限公司增資擴股暨引進投資者的議案》,同意公司全資子公司山東魯抗生物技術開發有限公司(“生物技術開發公司”)通過增資擴股方式引進戰略投資

根據國有資產管理關規定,公司分別聘請了上會會計師事務所(特殊普通合夥)及中瑞世聯資產評估集團有限公司對生物技術開發公司進行了審計和評估報經華魯控股集團有限公司核准後,2020124日至2021129日在山東產權交易中心進行公開掛牌徵集符合條件資者,掛牌價格為1.00492/最終韓國株式會社好麗友控股(好麗友控股)及好麗友食品有限公司(好麗友中國)成功競標增資擴股後的生物技術開發公司註冊資本為2億元人民幣,首期出資1.2億元其中好麗友控股出資6029.52萬元(6000萬股),佔比50%;好麗友中國出資1808.856萬元(1800萬股),佔比15%公司出資4218.204萬元(4200股),佔比35%

近日,公司收到生物技術開發公司通知,生物技術開發公司已辦理完成本次增資相關工商變更登記手續並領取由濟寧高新技術產業開發區市場監督管理局換髮的《營業執照》。

次增資擴股完成後,公司持有生物技術開發公司的股權比例由增資前的100%更為35%,不再納入合併報表範圍。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account